Haemonetics Corporation (HAE): Price and Financial Metrics


Haemonetics Corporation (HAE)

Today's Latest Price: $106.95 USD

0.33 (0.31%)

Updated Oct 23 7:00pm

Add HAE to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 142 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

HAE Stock Summary

  • HAE's current price/earnings ratio is 56.21, which is higher than 84.18% of US stocks with positive earnings.
  • Price to trailing twelve month operating cash flow for HAE is currently 32.08, higher than 87.76% of US stocks with positive operating cash flow.
  • Over the past twelve months, HAE has reported earnings growth of 97.64%, putting it ahead of 88.16% of US stocks in our set.
  • Stocks that are quantitatively similar to HAE, based on their financial statements, market capitalization, and price volatility, are UCTT, INGN, ITI, POWL, and LNN.
  • Visit HAE's SEC page to see the company's official filings. To visit the company's web site, go to www.haemonetics.com.

HAE Stock Price Chart Interactive Chart >

Price chart for HAE

HAE Price/Volume Stats

Current price $106.95 52-week high $130.75
Prev. close $106.62 52-week low $63.41
Day low $105.77 Volume 349,877
Day high $107.01 Avg. volume 578,810
50-day MA $90.41 Dividend yield N/A
200-day MA $98.09 Market Cap 5.42B

Haemonetics Corporation (HAE) Company Bio


Haemonetics designs, manufactures, and markets blood management solutions. The Company serves in three markets, such as manufacturers of plasma-derived pharmaceuticals, blood collectors, and hospitals. The company was founded in 1971 and is based in Braintree, Massachusetts.

HAE Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$106.95$466.12 340%

Below please find a table outlining a discounted cash flow forecast for HAE, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Haemonetics Corp ranked in the 75th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for Haemonetics Corp ended up being:

  • The compound growth rate in the free cash flow of Haemonetics Corp over the past 5.21 years is 0.86%; that's higher than 84.41% of free cash flow generating stocks in the Healthcare sector.
  • The business' balance sheet suggests that 9% of the company's capital is sourced from debt; this is greater than merely 21.5% of the free cash flow producing stocks we're observing.
  • HAE's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 38.77% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%331%
1%336%
2%340%
3%344%
4%349%
5%353%

Want more companies with a valuation profile/forecast similar to that of Haemonetics Corp? See ABBV, PRSC, RDNT, CVS, and MYL.


HAE Latest News Stream


Event/Time News Detail
Loading, please wait...

HAE Latest Social Stream


Loading social stream, please wait...

View Full HAE Social Stream

Latest HAE News From Around the Web

Below are the latest news stories about Haemonetics Corp that investors may wish to consider to help them evaluate HAE as an investment opportunity.

Haemonetics To Present At The 18th Annual Morgan Stanley Global Healthcare Conference

BOSTON, Sept. 9, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 18th Annual Morgan Stanley Virtual Global Healthcare Conference on Tuesday, Sept. 15, 2020, at 9:30 a.m. ET. The public may access Mr. Simon's…

PR Newswire | September 9, 2020

Haemonetics EPS beats by $0.05, misses on revenue

Haemonetics (HAE): Q1 Non-GAAP EPS of $0.46 beats by $0.05; GAAP EPS of $0.21 beats by $0.09.Revenue of $195.58M (-18.0% Y/Y) misses by $2.69M.Press Release...

Seeking Alpha | August 4, 2020

Haemonetics Announces Sale Of Inlog Holdings France SAS To Abénex Capital

Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to sell its wholly-owned subsidiary Inlog Holdings France SAS to Abénex. Abénex is a fully independent private equity firm based in France. Inlog Holdings France SAS, through its subsidiary In Log SAS, develops and sells blood bank and hospital software solutions used predominantly in France and in several other countries outside of the U.S.

Yahoo | July 24, 2020

Top 5 Q2 Buys of the Tweedy Browne Global Value Fund

Global investor focuses on positions in several ‘boring’ businesses Continue reading...

Yahoo | July 22, 2020

Did Hedge Funds Make The Right Call On Haemonetics Corporation (HAE) ?

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]

Yahoo | July 10, 2020

Read More 'HAE' Stories Here

HAE Price Returns

1-mo 23.44%
3-mo 17.30%
6-mo -10.06%
1-year -10.43%
3-year 128.72%
5-year 230.09%
YTD -6.92%
2019 14.84%
2018 72.26%
2017 44.48%
2016 24.69%
2015 -13.84%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.819 seconds.